Mark Offer

740 total citations
17 papers, 512 citations indexed

About

Mark Offer is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Mark Offer has authored 17 papers receiving a total of 512 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 5 papers in Hematology and 4 papers in Oncology. Recurrent topics in Mark Offer's work include Amyloidosis: Diagnosis, Treatment, Outcomes (15 papers), Multiple Myeloma Research and Treatments (4 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (3 papers). Mark Offer is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (15 papers), Multiple Myeloma Research and Treatments (4 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (3 papers). Mark Offer collaborates with scholars based in United Kingdom, United States and Canada. Mark Offer's co-authors include Helen J. Lachmann, Philip N. Hawkins, Julian D. Gillmore, Ashutosh Wechalekar, Hugh J. B. Goodman, Mark B. Pepys, Jayshree Joshi, Glenys A. Tennent, David J. Millar and J. Ruth Gallimore and has published in prestigious journals such as Blood, British Journal of Haematology and Haematologica.

In The Last Decade

Mark Offer

17 papers receiving 499 citations

Peers

Mark Offer

GENET

ONCOL

HEMAT

EPIDE

Gabriele Sarais Italy

Lisa Rannigan United Kingdom

David Lavergne France

Karen Wells United States

Darren Foard United Kingdom

DV Faller United States

Irini Xilouri Greece

Constantinos Pamboukas Greece

S. Mellou Greece

Saulius Girnius United States

Gabriele Sarais Italy

Mark Offer

466 ×1.0

129 ×0.8

GENET

119 ×0.9

ONCOL

88 ×0.7

HEMAT

94 ×0.8

EPIDE

Citations per year, relative to Mark Offer Mark Offer (= 1×) peers Gabriele Sarais

Countries citing papers authored by Mark Offer

Since Specialization

Citations

This map shows the geographic impact of Mark Offer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Offer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Offer more than expected).

Fields of papers citing papers by Mark Offer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Offer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Offer. The network helps show where Mark Offer may publish in the future.

Co-authorship network of co-authors of Mark Offer

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Offer. A scholar is included among the top collaborators of Mark Offer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Offer. Mark Offer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Kishore, Bhuvan, Matthew Jenner, Kevin Boyd, et al.. (2020). Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (≥2nd relapse) refractory myeloma: a multicenter real world UK experience. Leukemia & lymphoma. 62(6). 1396–1404. 5 indexed citations

Offer, Mark, et al.. (2015). The serological diagnostic challenges of multiple myeloma. British Journal of Hospital Medicine. 76(2). 84–88. 2 indexed citations

Sachchithanantham, Sajitha, Mark Offer, Christopher P. Venner, et al.. (2015). Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis. Haematologica. 100(11). 1469–1476. 11 indexed citations

Gillmore, JD, Helen J. Lachmann, Thirusha Lane, et al.. (2010). CTD versus Mel-Dex as upfront treatment in AL amyloidosis: a matched case-control study. UCL Discovery (University College London). 3 indexed citations

Gillmore, Julian D., Glenys A. Tennent, Winston L. Hutchinson, et al.. (2010). Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. British Journal of Haematology. 148(5). 760–767. 102 indexed citations

Gibbs, Simon, Julian D. Gillmore, Prayman Sattianayagam, et al.. (2009). In AL Amyloidosis, Both Oral Melphalan and Dexamethasone (Mel-Dex) and Risk-Adapted Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Have Similar Efficacy as Upfront Treatment.. Blood. 114(22). 745–745. 8 indexed citations

Lachmann, Helen J., et al.. (2008). Treatment of cryopyrin associated periodic fever syndrome with a fully human anti-IL-1beta monoclonal antibody (ACZ885): results from a subcutaneous administration study. UCL Discovery (University College London). 4 indexed citations

Wechalekar, Ashutosh, Helen J. Lachmann, Mark Offer, Philip N. Hawkins, & Julian D. Gillmore. (2008). Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica. 93(2). 295–298. 89 indexed citations

Wechalekar, Ashutosh, Mark Offer, Julian D. Gillmore, Philip N. Hawkins, & Helen J. Lachmann. (2008). Cardiac amyloidosis, a monoclonal gammopathy and a potentially misleading mutation. Nature Clinical Practice Cardiovascular Medicine. 6(2). 128–133. 15 indexed citations

10.

Sattianayagam, Prayman, Helen J. Lachmann, Mark Offer, et al.. (2008). Risk-Adapted Cyclophosphamide, Thalidomide and Dexamethasone (CTD) for the Treatment of Systemic AL Amyloidosis: Long Term Outcomes among 202 Patients.. Blood. 112(11). 1733–1733. 1 indexed citations

11.

Offer, Mark, et al.. (2006). Natural history and outcome of amyloidosis in the elderly. UCL Discovery (University College London). 1 indexed citations

12.

Wechalekar, Ashutosh, Julian D. Gillmore, Helen J. Lachmann, Mark Offer, & Philip N. Hawkins. (2006). Efficacy and Safety of Bortezomib in Systemic AL Amyloidosis - A Preliminary Report.. Blood. 108(11). 129–129. 10 indexed citations

13.

Wechalekar, Ashutosh, Hugh J. B. Goodman, Helen J. Lachmann, et al.. (2006). Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood. 109(2). 457–464. 168 indexed citations

14.

Gillmore, Julian D., Hugh J. B. Goodman, Helen J. Lachmann, et al.. (2005). Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood. 107(3). 1227–1229. 82 indexed citations

15.

Offer, Mark, Ashutosh Wechalekar, Hugh J. B. Goodman, et al.. (2005). Standard Oral Melphalan Chemotherapy for AL Amyloidosis Revisited Using the Serum Free Light Chain Assay.. Blood. 106(11). 3495–3495. 2 indexed citations

16.

Wechalekar, Ashutosh, Hugh J. B. Goodman, Julian D. Gillmore, et al.. (2005). Efficacy of Risk Adapted Cyclophosphamide, Thalidomide and Dexamethasone in Systemic AL Amyloidosis.. Blood. 106(11). 3496–3496. 7 indexed citations

17.

Wechalekar, Ashutosh, Helen J. Lachmann, Julian D. Gillmore, et al.. (2005). The Role of Renal Transplantation in Systemic AL Amyloidosis.. Blood. 106(11). 3497–3497. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact